Abstract 560: High levels of baseline ctDNA constitute a poor prognostic factor in progression-free survival in patients receiving neo-adjuvant chemo-immunotherapy: Results from NADIM clinical trial

• Published in: Cancer research (Chicago, Ill.) Vol. 81; no. 13_Supplement; p. 560
• Main Authors: Provencio, Mariano, Serna-Blasco, Roberto, Nadal, Ernest, Insa, Amelia, Garcia-Campelo, M. Rosario, Corbacho, Diego Pereiro, Domine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez-Marti, Alex, de Castro, Javier, Cobo, Manuel, Lopez-Vivanco, Guillermo, del Barco, Edel, Bernabe, Reyes, Viñolas, Nuria, Barneto, Isidoro, Viteri, Santiago, Pereira, Eva, Royuela, Ana, Casarrubios, Marta, Salas, Clara, Parra, Edwin R, Wistuba, Ignacio, Calvo, Virginia, Laza-Briviesca, Raquel, Massuti, Bartomeu, Cruz-Vermudez, Alberto, Romero, Atocha
• Format: Journal Article
• Language: English
• Published: 01.07.2021

Abstract There is growing evidence supporting that long-term survival of neoadjuvant chemo-immunotherapy for locally advanced NSCLC patients can be achieved. However, some patients invariably progress within the short-term. Identification of patients at high risk of progression is needed to achieve...